Messenger RNA (mRNA) is an emerging class of therapeutic agent for the prevention and
treatment of a wide range of diseases. The recent success of the two highly efficacious …

Lipid nanoparticles (LNPs) play an important role in mRNA vaccines against COVID-19. In
addition, many preclinical and clinical studies, including the siRNA-LNP product, Onpattro® …

Due to the fact that mRNA technology allows the production of diverse vaccines and
treatments in a shorter time frame and with reduced expense compared to conventional …

Antibodies against epitopes in S1 give the most accurate CoP against infection by the SARS‐
CoV‐2 coronavirus. Measurement of those antibodies by neutralization or binding assays …

Rare immune-mediated cardiac tissue inflammation can occur after vaccination, including
after SARS-CoV-2 mRNA vaccines. However, the underlying immune cellular and molecular …

After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more
than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 …

Lipid nanoparticle (LNP)-formulated messenger RNA (mRNA) vaccineare a promising
platform to prevent infectious diseases as demonstrated by the recent success of SARS-CoV …

Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …

Viral infections are a leading cause of myocarditis and pericarditis worldwide, conditions that
frequently coexist. Myocarditis and pericarditis were some of the early comorbidities …